- Signaling Pathways
- Antibody-Drug Conjugate/ADC Related
- Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.
All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.
The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.
All Product Categories
-
Antibody-Drug Conjugates (ADCs) Related Products (159)
Related Products (159)
- ADC Control Human IgG1-C24
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MDX-1203
0 ImagesCat. No.: HY-185484Synonyms: BMS-936561MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ZW-191
0 ImagesCat. No.: HY-185743ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Trastuzumab deruxtecan (DAR6)
0 ImagesCat. No.: HY-138298DCAS No.: 1826843-81-5Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Mocertatug rezetecan (DAR4)
0 ImagesCat. No.: HY-185280ACAS No.: 3042848-25-6Synonyms: HS-20089 (DAR4); GSK5733584 (DAR4)Mocertatug rezetecan (DAR4) (HS-20089 (DAR4); GSK5733584 (DAR4)) is an antibody-drug conjugate (ADC) targeting B7-H4, composed of Mocertatug (HY-P991703) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Mocertatug rezetecan (DAR4) delivers a TOPO1 inhibitor payload. It binds to B7-H4-expressing tumor cells, triggers ADC internalization, and induces S-phase cell cycle arrest, cytotoxicity, and bystander killing effect. Mocertatug rezetecan (DAR4) exhibits dose-dependent tumor growth inhibition in breast cancer and endometrial cancer CDX models. It can be used in research related to platinum-resistant ovarian cancer, breast cancer, endometrial cancer, cholangiocarcinoma, and cervical cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Trastuzumab-DM21
0 ImagesCat. No.: HY-185780Synonyms: T-DM21Trastuzumab-DM12 (T-DM21) is an antibody-drug conjugate (ADC). Trastuzumab-DM12 binds to HER2, inhibits HER2 shedding, and mediates antibody-dependent cellular cytotoxicity. Trastuzumab-DM12 is formed by conjugating the antibody Trastuzumab (HY-P9907) with DM-21 (HY-139441). Trastuzumab-DM12 can be used for cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Pertuzumab-LD3
0 ImagesCat. No.: HY-185460Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonal antibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine
0 ImagesCat. No.: HY-185775ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine is an isotype control antibody-drug conjugate for MEDI3726 (HY-185729). It carries hinge mutations including C214S in the light chain and C226V/C229V in the heavy chain, and the toxic molecule-linker conjugate is Tesirine (HY-128952). ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine can be used in the research of prostate cancer and metastatic castration-resistant prostate cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Enapotamab vedotin
0 ImagesCat. No.: HY-P99921CAS No.: 1912424-97-5Synonyms: HuMax-AXL-ADCEnapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rolinsatamab talirine
0 ImagesCat. No.: HY-P99881CAS No.: 2095467-44-8Synonyms: ABBV 176Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA
0 ImagesCat. No.: HY-171685Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker MC-Vc-PAB-DMEA-PEG2 and the DNA alkylator Duocarmycin SA (HY-12456). Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Trastuzumab-DM4
0 ImagesCat. No.: HY-185718Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR4)
0 ImagesCat. No.: HY-185774AADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) is a control antibody-drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 4, formed by the conjugation of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100) and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) serves as the isotype control for Farletuzumab-LNK4-S (DAR4) (HY-185773A). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CD388
0 ImagesCat. No.: HY-185821CD388 is an antiviral reagent-Fc conjugate formed by linking an influenza virus neuraminidase inhibitor to the CH1-Fc hybrid domain of IgG1. CD388 exerts antiviral activity extracellularly by inhibiting Neuraminidase. CD388 reduces pulmonary viral load and proinflammatory cytokine levels in influenza-infected mice, prevents death, reduces body weight loss, and prolongs median time to death. CD388 exhibits activity against influenza A and B subtypes, including highly pathogenic strains. CD388 can be used in influenza-related research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Epratuzumab Tesirine
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1-JSSW-001
0 ImagesCat. No.: HY-185833ADC Control Human IgG1-JSSW-001 is the isotype control for ADC SYS6010 (HY-185832). SYS6010 is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR), which is formed by conjugating the anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) with the topoisomerase I inhibitor JS-1 (HY-178217) via a cleavable tetrapeptide linker. SYS6010 can be used in the research of advanced solid tumors such as non-small cell lung cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-VcMMAE
0 ImagesCat. No.: HY-171683Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-SMCC-DM1
0 ImagesCat. No.: HY-171680Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker SMCC (HY-42360) and the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-CCL2 (Carlumab)-SMCC-DM1 can be used in the research of cancer, especially prostate cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38
0 ImagesCat. No.: HY-171738Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ZW-251
0 ImagesCat. No.: HY-185742ZW-251 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) with topoisomerase-I inhibitory activity. ZW-251 induces cytotoxicity, penetrates tumor spheroids, exerts bystander cytotoxicity, and inhibits tumor growth in hepatocellular carcinoma models. ZW-251 can be used for the research of hepatocellular carcinoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -